Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... HBV DNA at Week 24, analyzed by linear regression and adjusted for baseline HBV DNA and lamivudine resistance status. The study successfully met its primary objective; at Week 24, ...
2009 NOV 1 ... Results of MERIT at 48-weeks showed that Selzentry plus Combivir® (zidovudine/lamivudine) was as effective as Sustiva® (efavirenz) plus zidovudine...
2009 NOV 16 ... together with the previously demonstrated inhibitory activity of MIV-210 against lamivudine-, adefovir-, and entecavir-resistant HBV variants, make MIV-210 a highly valuable ...
2009 NOV 16 ... regimen were initiated on treatment with efavirenz at 600 mg/day plus stavudine-lamivudine. Fasting efavirenz concentrations at 12 h after dosing (C-12) were monitored." ...
2009 NOV 16 ... of patients were treatment-naive upon study initiation, although some patients were lamivudine-experienced. Patients originally randomized to Hepsera in both studies ...
2009 NOV 9 ... seven of 338 (90.8%) patients had previously received stavudine and/or zidovudine + lamivudine + efavirenz or nevirapine; 41 of 338 (12.1%) had received tenofovir (TDF). The most ...
2009 OCT 12 ... score (number of drugs in the combination among zidovudine, abacavir, stavudine, lamivudine, efavirenz, nevirapine, indinavir, and lopinavir-ritonavir) and the CNS ...
2009 NOV 2 ... Research findings, 'Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B,' are ...
2009 NOV 23 ... study (ETV-022) where patients were randomized to entecavir 0.5 mg/day (n = 354) or lamivudine 100 mg/day (n = 355) once daily," scientists writing in the Journal of Viral Hepatitis ...
2009 NOV 9 ... treatment failures, virologic suppression was finally achieved with a combination of lamivudine, abacavir, efavirenz, and lopinavir/ritonavir." Dinavahi and colleagues ...
2009 OCT 12 ... from Liverpool, the United Kingdom, "Tenofovir/emtricitabine (TDF/FTC) and abacavir/lamivudine (ABC/3TC) are widely used with ritonavir (RTV)-boosted protease inhibitors (PIs) as ...
2009 NOV 16 ... (HBV) infections. We evaluated the efficacy of ETV in patients who were resistant to lamivudine (LAM)/ADV sequential therapy and in those resistant to LAM monotherapy," scientists ...
2009 NOV 16 ... antiretroviral therapy (cART) containing tenofovir (TDF) and abacavir (ABC) with lamivudine leads to unacceptably high virological failure rates with frequent selection of reverse ...
2009 OCT 12 ... diagnosis received standard anti-TB therapy and a fixed-dose combination of stavudine, lamivudine, and NVP. Full NVP pharmacokinetic curves were calculated at 4 (T1) and 10 weeks (T2) of ...
2009 NOV 16 ... it a viable second-line treatment option in patients who have failed regimens containing lamivudine or emtricitabine." Gaffney and colleagues published their study in Annals ...
2009 NOV 1 ... or a low dose (70% of the standard dose) twice daily in combination with zidovudine and lamivudine. A 12 h pharmacokinetic study was done at 4-6 weeks after starting treatment. Treatment ...
2009 NOV 16 ... 169 individuals: 53 (31.4%) patients were ART-naive, 46 (27.2%) were under ART without Lamivudine or tenofovir, and the remaining 70 (41.4%) were under ART including...
